Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie’s Downward Humira Guidance Worries Analysts

Executive Summary

Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.

You may also be interested in...



AbbVie CEO Upbeat On Skyrizi Commercialization, Raises Financial Guidance

AbbVie’s product pipeline may be delivering just in time to alleviate concerns about loss of exclusivity on its best-selling product, Humira.

 

AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.

AbbVie's 'Unjustified' Humira Settlements Divide Market, Claims Class Action

First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC124549

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel